Canada markets open in 3 hours 32 minutes

Zymeworks Inc. (ZYME.TO)

Toronto - Toronto Delayed Price. Currency in CAD
Add to watchlist
33.10+0.53 (+1.63%)
At close: 3:58PM EDT
Sign in to post a message.
  • M
    Mark
    Raymond James Analysts Give Zymeworks (NYSE:ZYME) a $74.00 Price Target
  • a
    arthur
    what up with Zymeworks report seemed okay but stock keeps losing ground? Also a couple of upgrades .
  • D
    Davebiotech
    3/6PR's 2 SD in 3-4 line pts. Big deal for a Co with $1Bln plus mkt cap. Tox profiloe is great in these pts tho. No wonder the sell off. But nows the time to buy. I like the Bispecific Her2 ADC. First of its kind.
  • m
    mg
    Problem here was the presentation during the whole conference call. Was followed up by a Q/A that left everyone with questions. Nothing sounded convincing. Add that to the CMO and VP selling their shares in the 50's and this is what you get. It was an oversell for sure. Zanidatamab and partners studies will carry this along. Plus the fact ZW49 is moving forward but with unanswered questions the street obviously needs answers to.
  • D
    Daniel S
    My experience with all pharma stocks I've owned is that if you play the long game sooner or later there will be a big pay out but also huge dips along the way and more so than other sectors, pharma stocks are only for the long haul investors in my opinion.
  • s
    stocktargetadvisor
    $ZYME
    Target Raised by Wells Fargo Overweight USD 58 » USD 71
    Maintains SVB Leerink Outperform USD 45 » USD 66
  • N
    Nessa
    Companies CFO and CEO sold bunch of shares mid December ! No wonder stocks drop. Hopefully this is not an indication of bearish for January presentation
  • s
    stocktargetadvisor
    $ZYME
    Target Lowered by SVB Leerink Outperform USD 66 » USD 50
    Target Lowered by Barclays Equal Weight USD 47 » USD 38
  • a
    arthur
    What’s up with after hours? They release the new story didn’t seem to be negative any thoughts
  • a
    arthur
    you got a love these analysts two days ago they raise the price target to 70 now they downgraded between 36 to 50 no scam there
  • J
    JohnD
    DB commentary:
    Zymeworks (ZYME)

    Zymeworks wants to help bring patients home disease free, developing treatments for various forms of cancer as well as tumors. After gaining 187% year-to-date, the biotech company is definitely on the Street’s radar.

    During the ESMO Asia 2019, the company provided an update on the first part of the Phase 1 trial evaluating single-agent ZW25 in HER2+ cancers, not including breast cancer. The data demonstrated that response rates improved for colorectal cancer and gastroesophageal adenocarcinoma, with ZW25's safety profile still looking promising. Most noteworthy, however, was that one pancreatic cancer patient experienced a 100% decrease in target lesions.

    “Overall, we view the ESMO Asia update as continuing to support the broad activity of ZW25 monotherapy in HER2+ cancers, especially in HER2-high cancers, with a safety profile that appears highly amenable to combination approaches. Further, first responses in duodenal and pancreatic tumors expand the breadth of that clinical activity and provide more reasons for us to be enthusiastic with regard to the company,”
  • a
    arthur
    Looking forward to January’s presentations! Hopefully they share some more good news with us.
  • J
    JohnD
    $166 million in cash/cash equivalents and world class partners - just put some more in my son's account. Along with ALRN and OMER - expect to cash this trifecta for large gains within a few years.
  • a
    arthur
    Quite a bit of buy recommendations today the highest one I saw was 65 let’s hope the right
  • J
    JohnD
    Stifel joins the party - initiates coverage with buy rating and $45 price target.
  • B
    BUYGOLD
    Looks very promising. If even one of their drugs gets approved, the combination of revenue from that, coupled with ongoing partnerships could make this a blockbuster of a company. IMO Unlike many, this is way beyond a one trick pony.
  • S
    Sam
    earnings showed no or little revenue so when will the billions roll in ?
  • B
    BrianM
    Bought today due to the risk/reward set up. Bought 50% of a position to add on further weakness. I see about another $9 down as the max down sides and over $20 up. I will take those odds here. Also always have the potential of ELY increasing their stake here to take more share off the float.
  • J
    JohnD
    Nice analyst trendline Deutsche Bank goes from$39-49; Landerburg from $41-58; Raymond James from $40-60 and Wainwright initiates at $65.

    I've been in Zyme since the low teens and not going to sell a single share (apart from the occasional covered call that gets exercised).
  • D
    Delivery Guy
    ImmunoPrecise Announces New Multi-Specific SARS-CoV-2 Antibody Collaboration with Zymeworks

    VICTORIA, BC, Sept. 17, 2020 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTCQB: IPATF) (FSE: TQB2), a leader in full-service, therapeutic antibody discovery and development, announce a research collaboration with Zymeworks Inc., giving ImmunoPrecise access to Zymeworks' Azymetric™ and EFECT™ platforms for the further development of its multiple antibody candidates to fight COVID-19.

    Under the terms of the agreement, IPA will transform its previously tested and potent SARS-CoV-2 neutralizing antibodies into bispecific and multispecific antibodies using the Zymeworks' platforms. These sets of candidates will be thoroughly tested using SARS-CoV-2 spike protein provided by the National Research Council Canada ("NRC"), prior to pre-clinical manufacturing at the NRC for animal studies. Timelines for the Companies pre-clinical studies examining the efficacy of IPA's Polytope therapies using traditional antibody formats are not impacted by these additional investigations into formulation.

    "Global health issues like the COVID-19 pandemic represent significant times for companies like IPA to share our collective expertise and technologies to bring forward safe and efficacious therapies," said Ali Tehrani, Ph.D., President and CEO of Zymeworks. "We look forward to continuing our relationship with ImmunoPrecise as they advance multi-specific candidates toward the clinic."

    "After the discovery of potently neutralizing antibodies in a combinatorial setting, it was a logical consequence for us to look into clinically-proven, multi-specific antibody platforms," said Jennifer Bath, Ph.D., President and CEO of ImmunoPrecise Antibodies. "IPA is pleased to collaborate with the Zymeworks team as we work together to treat COVID patients using our extensive, collective expertise."

    Jennifer Bath, Ph.D., Chief Executive Officer of ImmunoPrecise, has reviewed and approved the scientific disclosure of this news release.

    The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain COVID-19 (or SARS-CoV-2) at this time.